Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 11.1.2021 | EN | Official Journal of the European Union | C 8/14 |

---

Prior notification of a concentration

(Case M.9945 — Siemens Healthineers AG/Varian Medical Systems)

(Text with EEA relevance)

(2021/C 8/05)

1.

On 23 December 2020, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2021008EN.01001401-E0001).

This notification concerns the following undertakings:

|  |  |
| --- | --- |
| — | Siemens Healthineers AG (‘Siemens Healthineers’, Germany), controlled by Siemens AG (Germany), |

|  |  |
| --- | --- |
| — | Varian Medical Systems, Inc. (‘Varian’, USA). |

Siemens Healthineers acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Varian.

The concentration is accomplished by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

|  |  |
| --- | --- |
| — | Siemens Healthineers is a stock corporation headquartered in Erlangen (Germany) and listed on the Frankfurt Stock Exchange. Siemens Healthineers provides healthcare solutions and services worldwide under three business segments: (i) Imaging; (ii) Laboratory Diagnostics; and (iii) Advanced Therapies, |

|  |  |
| --- | --- |
| — | Siemens AG is a technology company headquartered in Munich (Germany). Siemens is active worldwide and focuses on the areas of automation and digitalization in the process and manufacturing industries, intelligent infrastructure for buildings and distributed energy systems, smart mobility solutions for rail and road and medical technology and digital healthcare services, |

|  |  |
| --- | --- |
| — | Varian is a public corporation headquartered in Palo Alto (USA) and listed on the New York Stock Exchange. Varian is a global provider of medical devices and software solutions for treating cancer and other medical conditions with radiation therapy and other advanced treatments. |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9945 – Siemens Healthineers/Varian Medical Systems

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

|  |
| --- |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

---

[Top](#document1)